Antibody Drug Conjugates
February 2020
in “
Oncology Times
”
TLDR Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
Antibody drug conjugates (ADCs) were a major advancement in targeted cancer therapy, combining cytotoxic agents with tumor-specific antibodies to minimize systemic toxicity and effectively kill cancer cells. By 2020, several ADCs were approved for treating cancers like leukemia, lymphoma, and breast cancer, showing improved survival and response rates in patients with limited options. Despite promising results, challenges such as drug resistance, toxicity management, and the complexity of ADC design persisted. Ongoing research and technological advancements were anticipated to enhance ADC applications, efficacy, and safety.
